Penetration of intravesical doxorubicin in human bladders

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 6, 1996, Pages 539-546

  Wientjes, M Guillaume ^a   Badalament, Robert A ^a   Au, Jessie L S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bladder cancer; Doxorubicin

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER MUSCLE; BLADDER WALL; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTECTOMY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG URINE LEVEL; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL; UROTHELIUM;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; HUMANS; MIDDLE AGED; MITOMYCIN; TISSUE DISTRIBUTION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0029877376     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050426     Document Type: Article

References (26)

1. Fair WR, Fuks ZY, Scher HI (1993) Cancer of the bladder. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. Lippincott, Philadelphia, p 1052
2. Herr HW, Laudone VP, Whitmore WF Jr (1987) An overview of intravesical therapy for superficial bladder tumors. J Urol 138: 1363
3. Lum BL, Torti FM (1991) Adjuvant intravesical pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst 83: 682
4. Soloway MS (1980) Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 123: 466
5. Heney NM, Koontz WW, Barton B, Soloway M, Trump DL, Hazra T, Weinstein RS for the National Bladder Cancer Group (1988) Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol 140: 1390
6. Dalton JT, Wientjes GW, Badalament RA, Drago JR, Au JL-S (1991) Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51: 5144
7. Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL-S (1991) Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 51: 4347
8. Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL-S (1993) Penetration of mitomycin in human bladder. Cancer Res 53: 3314
9. Schmittgen TD, Weaver JM, Badalament RA, Wientjes MG, Klein E, Young D, Au JL-S (1994) Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology. J Urol 152: 1632
10. Wientjes MG, Badalament RA, Au JL-S (1993) Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 32: 255
11. Chai M, Wientjes MG, Badalament RA, Burgers JK, Au JL-S (1994) Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol 152: 374
12. Wientjes MG, Dalton JT, Badalament RA, Dasani BM, Drago JR, Au JL-S (1991) A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. Pharm Res 8: 168
13. Song D, Wientjes MG, Au JL-S (1994) Penetration of 5-fluorouridine in dog bladder wall. Proc Am Assoc Cancer Res 35: 432
14. See WA, Xia Q (1992) Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 84: 510
15. 3H-doxorubicin hydrochloride in men: plasma uptake and tumor penetration. J Urol 124: 34
16. Nakada T, Akiya T, Yoshikawa M, Koike H, Kayayama T (1985) Intravesical instillation of doxorubicin hydrochloride and its incorporation into bladder tumors. J Urol 134: 54
17. Garofalo F, Camaggi CM, Lalanne MG, De Santis P, Nanni G, Tisatto E, Secchiero S, Angelelli B, Pannuti F (1985) Plasma absorption and tissue concentrations of adriamycin during intravesical therapy. Ettore Majorana Int Sci Ser Life Sci 18: 391
18. Saika T, Tsushima T, Nasu Y, Noda M, Akebi N, Kaku S. Takamatsu M, Ohmori H, Uno S, Johsen T (1993) Tissue concentration of intravesically instilled (2′R)-4′-O-tetrahydropyranyl-adriamycin or adriamycin in superficial bladder cancer. Nippon Hinyokika Gakkai Zasshi 84: 1206
19. Mross K, Schultze-Seeman W, Burk K, Hossfeld DK (1992) Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumors. Cancer Chemother Pharmacol 29: 490
20. Wester RC, Maibach HI (1993) Percutaneous absorption. In: Shah VP, Maibach HI (eds) Topical drug bioavailability, bioequivalence, and penetration. Plenum, New York, p 3
21. Harris PA, Gross JF (1975) Preliminary pharmacokinetic model for adriamycin (NSC-123127). Cancer Chemother Rep 59: 819
22. Hartigh J den, McVie JG, Oort WJ van, Pinedo HM (1983) Pharmacokinetics of mitomycin C in humans. Cancer Res 43: 5017
23. Myers CE Jr, Chabner BA (1990) Anthracyclines. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practices. Lippincott, Philadelphia, p 356
24. Crooke ST, Henderson M, Samson M, Baker LH (1976) Phase I study of oral mitomycin C. Cancer Treat Rep 60: 1633
25. Alberts DS, Chen H-SG (1980) Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Salmon SE (ed) Cloning of human tumor stem cells. Liss, New York, p 351
26. Pauli BU, Alroy J, Weinstein RS (1983) The ultrastructure and pathobiology of urinary bladder cancer. In: Bryan GT, Cohen SM (eds) The pathology of bladder cancer, vol 2. CRC Press, Boca Raton, p 41